Application | Comment | Organism |
---|---|---|
medicine | prime target for development of anticancer therapeutics | Homo sapiens |
medicine | prime target for development of anticancer therapeutics | Toxoplasma gondii |
medicine | possibility of development of specific inhibitors for parasitic protozoa | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
farnesyltransferase inhibitors I and II | peptidomimemtic inhibitors, inhibitor I: 50% inhibition at 270 nM, inhibitor II: 50% inhibition at 0.97 nM | Toxoplasma gondii | |
KTSCVAM | 40% inhibition of farnesylation in Toxoplasma gondii, 100% inhibition of enzyme in HeLa cells | Homo sapiens | |
KTSCVAM | 40% inhibition of farnesylation in Toxoplasma gondii, 100% inhibition of enzyme in HeLa cells | Toxoplasma gondii | |
KTSCVFM | 80% inhibition of farnesylation in Toxoplasma gondii and 80% inhibition of enzyme in HeLa cells | Homo sapiens | |
KTSCVFM | 80% inhibition of farnesylation in Toxoplasma gondii and 80% inhibition of enzyme in HeLa cells | Toxoplasma gondii | |
KTSCVIA | 50% inhibition of farnesylation in Toxoplasma gondii and no inhibition of enzyme in HeLa cells | Homo sapiens | |
KTSCVIA | 50% inhibition of farnesylation in Toxoplasma gondii and no inhibition of enzyme in HeLa cells | Toxoplasma gondii | |
KTSCVIF | no inhibition of farnesylation in Toxoplasma gondii, 80% inhibition of enzyme in HeLa cells | Homo sapiens | |
KTSCVIF | no inhibition of farnesylation in Toxoplasma gondii, 80% inhibition of enzyme in HeLa cells | Toxoplasma gondii | |
KTSSVIM | 80% inhibition of farnesylation in Toxoplasma gondii, 100% inhibition of enzyme in HeLa cells | Homo sapiens | |
KTSSVIM | 80% inhibition of farnesylation in Toxoplasma gondii, 100% inhibition of enzyme in HeLa cells | Toxoplasma gondii | |
additional information | not: KTSSVIM | Homo sapiens | |
additional information | not: KTSSVIM | Toxoplasma gondii |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Mg2+ | required | Toxoplasma gondii | |
additional information | not: Ca2+ | Toxoplasma gondii | |
Zn2+ | required | Toxoplasma gondii | |
Zn2+ | optimal activity in the presence of 0.025 mM | Homo sapiens | |
Zn2+ | optimal activity in the presence of 0.025 mM | Toxoplasma gondii |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
farnesyl diphosphate + protein-cysteine | Toxoplasma gondii | enzyme responsible for catalysing isoprene lipid modifications | S-farnesyl protein + diphosphate | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
mammalian HeLa cells | - |
Toxoplasma gondii | - |
tachyzoites of the RH strain were grown and maintained in Cercopithecus aethiops kidney cells | - |
Purification (Comment) | Organism |
---|---|
- |
Toxoplasma gondii |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
farnesyl diphosphate + protein-cysteine | - |
Homo sapiens | diphosphate + S-farnesyl protein | - |
? | |
farnesyl diphosphate + protein-cysteine | substrate: Biotin lamin-B protein | Toxoplasma gondii | diphosphate + S-farnesyl protein | - |
? | |
farnesyl diphosphate + protein-cysteine | enzyme responsible for catalysing isoprene lipid modifications | Toxoplasma gondii | S-farnesyl protein + diphosphate | - |
? |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
36 | - |
- |
Toxoplasma gondii |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
8 | - |
- |
Toxoplasma gondii |
pH Minimum | pH Maximum | Comment | Organism |
---|---|---|---|
6 | 8.4 | pH 6.0 and pH .4: about 80% of maximal activity, the enzyme activity is completely abolished at pH 4.0 | Toxoplasma gondii |
pH Stability | pH Stability Maximum | Comment | Organism |
---|---|---|---|
4 | - |
the enzyme activity completely abolishes | Toxoplasma gondii |